Royce & Associates LP trimmed its stake in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 969,128 shares of the oil and gas company's stock after selling 51,993 shares during the quarter. Royce & Associates LP owned 2.06% of Core Laboratories worth $16,776,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Assetmark Inc. bought a new position in Core Laboratories in the 4th quarter worth about $26,000. Smartleaf Asset Management LLC increased its stake in Core Laboratories by 173.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,037 shares of the oil and gas company's stock worth $35,000 after acquiring an additional 1,293 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Core Laboratories by 2,688.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,426 shares of the oil and gas company's stock worth $42,000 after acquiring an additional 2,339 shares during the last quarter. Isthmus Partners LLC increased its stake in Core Laboratories by 18.8% in the 3rd quarter. Isthmus Partners LLC now owns 10,620 shares of the oil and gas company's stock worth $197,000 after acquiring an additional 1,682 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Core Laboratories in the 3rd quarter worth about $211,000. 97.81% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Separately, Citigroup upgraded Core Laboratories from a "sell" rating to a "neutral" rating and upped their target price for the stock from $15.00 to $16.00 in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company's stock. According to data from MarketBeat.com, Core Laboratories presently has a consensus rating of "Hold" and an average price target of $17.50.
Check Out Our Latest Stock Report on CLB
Core Laboratories Price Performance
Shares of Core Laboratories stock traded up $0.02 during trading on Thursday, hitting $15.40. 193,242 shares of the stock traded hands, compared to its average volume of 356,467. The company has a quick ratio of 1.71, a current ratio of 2.32 and a debt-to-equity ratio of 0.49. The stock has a market cap of $721.32 million, a price-to-earnings ratio of 23.34, a PEG ratio of 0.99 and a beta of 2.38. The firm's fifty day moving average is $16.90 and its 200-day moving average is $18.23. Core Laboratories Inc. has a 52 week low of $12.95 and a 52 week high of $25.13.
Core Laboratories (NYSE:CLB - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The oil and gas company reported $0.23 EPS for the quarter, meeting the consensus estimate of $0.23. Core Laboratories had a return on equity of 16.24% and a net margin of 5.99%. Research analysts expect that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.
Core Laboratories Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Monday, February 10th were issued a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend was Monday, February 10th. Core Laboratories's dividend payout ratio is presently 6.06%.
Core Laboratories Company Profile
(
Free Report)
Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.
Featured Articles
Before you consider Core Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.
While Core Laboratories currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
